Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9332345 | 1.00 | RNPEP (0.48) | RNPEPFOLH1TSHRLMNAALDH1A1 | |
| SCHEMBL2820915 | 1.00 | RNPEP (0.48) | RNPEPFOLH1TSHRLMNAALDH1A1 | |
| SCHEMBL18251760 | 0.86 | RNPEP (0.41) | RNPEPFOLH1TSHRALDH1A1CHRM2 | |
| SCHEMBL10638968 | 0.85 | RNPEP (0.41) | RNPEPFOLH1TSHRALDH1A1ALOX15 | |
| SCHEMBL10642174 | 0.85 | RNPEP (0.33) | RNPEPFOLH1TSHRALOX15 | |
| SCHEMBL23069667 | 0.82 | RNPEP (0.38) | RNPEPFOLH1TSHRALDH1A1L3MBTL1 | |
| SCHEMBL28648380 | 0.82 | RNPEP (0.47) | RNPEPFOLH1LMNAALDH1A1MAPK1 | |
| SCHEMBL9194615 | 0.82 | RNPEP (0.38) | RNPEPFOLH1TSHRLMNAALDH1A1 | |
| SCHEMBL10642169 | 0.82 | RNPEP (0.42) | RNPEPFOLH1TSHRALDH1A1CHRM2 | |
| SCHEMBL18255177 | 0.82 | RNPEP (0.38) | RNPEPFOLH1TSHRALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0133796-B1 | PROCESS FOR PREPARATION OF METHIONINE HYDROXY ANALOG OR DERIVATIVE AND ESTERS THEREOF, AND FOR THE PREPARATION OF 1-ACYLOXY-3-HYDROCARBYL THIOPROPENES | THE STANDARD OIL COMPANY (US) | 1987-03-04 | — | — | EP | claimed |
| EP-0133796-A1 | Process for preparation of methionine hydroxy analog or derivative and esters thereof, and for the preparation of 1-acyloxy-3-hydrocarbyl thiopropenes | THE STANDARD OIL COMPANY (US) | 1985-03-06 | — | — | EP | claimed |
| CN-114341107-A | Process for preparing alpha-hydroxy esters by esterifying alpha-hydroxy acids | 建明实业股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-108291055-B | Sulfur-containing compounds as solvents | 诺华丝国际股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-112707851-A | Sulfur-containing compounds as solvents | 诺华丝国际股份有限公司 | 2021-04-27 | — | — | CN | disclosed |
| WO-2021046234-A1 | PROCESSES FOR THE PREPARATION OF ALPHA-HYDROXY ESTERS BY ESTERIFICATION OF ALPHA-HYDROXY ACIDS | KEMIN INDUSTRIES, INC. (US) | 2021-03-11 | — | — | WO | disclosed |
| EP-2800737-B1 | SULFOXIDE-BASED SURFACTANTS | NOVUS INT INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10227551-B2 | Sulfur-containing compounds as solvents | NOVUS INTERNATIONAL, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-3374428-A1 | SULFUR-CONTAINING COMPOUNDS AS SOLVENTS | Novus International Inc. (US) | 2018-09-19 | — | — | EP | disclosed |
| US-10023825-B2 | Sulfoxide-based surfactants | NOVUS INTERNATIONAL, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9902690-B2 | Ethoxylated surfactants | NOVUS INTERNATIONAL, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| EP-0504266-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5075502-A | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1991-12-24 | — | — | US | disclosed |
| WO-1991009007-A2 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT, INC. (US) | 1991-06-27 | — | — | WO | disclosed |
| US-4954647-A | Process for optically active 3-(methane-sulfonyloxy) thiolane and analogs | PFIZER INC. (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0338735-A1 | Process for optically active 3-(methane-sulfonyloxy)thioland and analogs | PFIZER INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| US-4874877-A | Process for optically active 3-(methane-sulfonyloxy)thiolane and analogs | PFIZER INC. (US) | 1989-10-17 | — | — | US | disclosed |
| US-4782173-A | ANIMAL FEEDS | THE STANDARD OIL COMPANY (US) | 1988-11-01 | — | — | US | disclosed |
| EP-0133796-B1 | PROCESS FOR PREPARATION OF METHIONINE HYDROXY ANALOG OR DERIVATIVE AND ESTERS THEREOF, AND FOR THE PREPARATION OF 1-ACYLOXY-3-HYDROCARBYL THIOPROPENES | THE STANDARD OIL COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0133796-A1 | Process for preparation of methionine hydroxy analog or derivative and esters thereof, and for the preparation of 1-acyloxy-3-hydrocarbyl thiopropenes | THE STANDARD OIL COMPANY (US) | 1985-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227551-B2 | Sulfur-containing compounds as solvents | TST, CBS, MPST | RNPEP 2501/4885FOLH1 2446/4885TSHR 4705/4885 |
| US-10023825-B2 | Sulfoxide-based surfactants | STS, SGMS1, SGMS2 | RNPEP 2401/4885FOLH1 3176/4885TSHR 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.